VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

GSK1437173A
Vaccine Information
  • Vaccine Name: GSK1437173A
  • Target Pathogen: Herpes simplex virus type 1 and 2
  • Target Disease: Herpes
  • Product Name: Herpes Zoster vaccine GSK1437173A
  • Vaccine Ontology ID: VO_0004598
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Antigen: Glycoprotein E (gE) (Chlibek et al., 2013)
  • US8 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Baboon Response

  • Vaccination Protocol: This project was a phase II, observer-blind, randomized, multinational study. Adults ≥50 years old were randomized 4:4:2:1 to be vaccinated at months 0 and 2 with gE combined with a higher (AS01B) or lower (AS01E) dose adjuvant, unadjuvanted gE, or saline (Chlibek et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Cell-mediated and humoral immune responses immune responses were significantly enhanced by AS01B and AS01E compared to unadjuvanted gE. gE/AS01B induced stronger immune responses than gE/AS01E (Chlibek et al., 2013).
  • Side Effects: No vaccine-related severe adverse events were reported, and solicited adverse events were generally mild to moderate and transient. For all gE-based vaccines, pain was the most common local symptom and fatigue the most common general symptom (Chlibek et al., 2013).
References
Chlibek et al., 2013: Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age. The Journal of infectious diseases. 2013; ; . [PubMed: 23904292].